Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

Blood platelets in the progression of Alzheimer's disease.

Gowert NS, Donner L, Chatterjee M, Eisele YS, Towhid ST, Münzer P, Walker B, Ogorek I, Borst O, Grandoch M, Schaller M, Fischer JW, Gawaz M, Weggen S, Lang F, Jucker M, Elvers M.

PLoS One. 2014 Feb 28;9(2):e90523. doi: 10.1371/journal.pone.0090523. eCollection 2014.

2.

Pre-activated blood platelets and a pro-thrombotic phenotype in APP23 mice modeling Alzheimer's disease.

Jarre A, Gowert NS, Donner L, Münzer P, Klier M, Borst O, Schaller M, Lang F, Korth C, Elvers M.

Cell Signal. 2014 Sep;26(9):2040-50. doi: 10.1016/j.cellsig.2014.05.019. Epub 2014 Jun 11.

PMID:
24928203
3.

Platelets in the Alzheimer's disease brain: do they play a role in cerebral amyloid angiopathy?

Kniewallner KM, Ehrlich D, Kiefer A, Marksteiner J, Humpel C.

Curr Neurovasc Res. 2015;12(1):4-14.

4.

Reduced nitric oxide bioavailability mediates cerebroarterial dysfunction independent of cerebral amyloid angiopathy in a mouse model of Alzheimer's disease.

Merlini M, Shi Y, Keller S, Savarese G, Akhmedov A, Derungs R, Spescha RD, Kulic L, Nitsch RM, Lüscher TF, Camici GG.

Am J Physiol Heart Circ Physiol. 2017 Feb 1;312(2):H232-H238. doi: 10.1152/ajpheart.00607.2016. Epub 2016 Nov 11.

PMID:
27836896
5.

Cross-talk between Aβ and endothelial SSAO/VAP-1 accelerates vascular damage and Aβ aggregation related to CAA-AD.

Solé M, Miñano-Molina AJ, Unzeta M.

Neurobiol Aging. 2015 Feb;36(2):762-75. doi: 10.1016/j.neurobiolaging.2014.09.030. Epub 2014 Oct 13.

PMID:
25457560
6.

Vascular β-amyloid and early astrocyte alterations impair cerebrovascular function and cerebral metabolism in transgenic arcAβ mice.

Merlini M, Meyer EP, Ulmann-Schuler A, Nitsch RM.

Acta Neuropathol. 2011 Sep;122(3):293-311. doi: 10.1007/s00401-011-0834-y. Epub 2011 Jun 19.

7.

Murine versus human apolipoprotein E4: differential facilitation of and co-localization in cerebral amyloid angiopathy and amyloid plaques in APP transgenic mouse models.

Liao F, Zhang TJ, Jiang H, Lefton KB, Robinson GO, Vassar R, Sullivan PM, Holtzman DM.

Acta Neuropathol Commun. 2015 Nov 10;3:70. doi: 10.1186/s40478-015-0250-y.

8.

ABCG2 is upregulated in Alzheimer's brain with cerebral amyloid angiopathy and may act as a gatekeeper at the blood-brain barrier for Abeta(1-40) peptides.

Xiong H, Callaghan D, Jones A, Bai J, Rasquinha I, Smith C, Pei K, Walker D, Lue LF, Stanimirovic D, Zhang W.

J Neurosci. 2009 Apr 29;29(17):5463-75. doi: 10.1523/JNEUROSCI.5103-08.2009.

9.

Cerebral amyloid angiopathy and its relationship to Alzheimer's disease.

Thal DR, Griffin WS, de Vos RA, Ghebremedhin E.

Acta Neuropathol. 2008 Jun;115(6):599-609. doi: 10.1007/s00401-008-0366-2. Epub 2008 Mar 28. Review.

PMID:
18369648
10.

Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease.

Bell RD, Zlokovic BV.

Acta Neuropathol. 2009 Jul;118(1):103-13. doi: 10.1007/s00401-009-0522-3. Epub 2009 Mar 25. Review.

11.

Resorufin analogs preferentially bind cerebrovascular amyloid: potential use as imaging ligands for cerebral amyloid angiopathy.

Han BH, Zhou ML, Vellimana AK, Milner E, Kim DH, Greenberg JK, Chu W, Mach RH, Zipfel GJ.

Mol Neurodegener. 2011 Dec 22;6:86. doi: 10.1186/1750-1326-6-86.

12.

Overexpression of human S100B exacerbates cerebral amyloidosis and gliosis in the Tg2576 mouse model of Alzheimer's disease.

Mori T, Koyama N, Arendash GW, Horikoshi-Sakuraba Y, Tan J, Town T.

Glia. 2010 Feb;58(3):300-14. doi: 10.1002/glia.20924.

13.

Hereditary and sporadic forms of abeta-cerebrovascular amyloidosis and relevant transgenic mouse models.

Kumar-Singh S.

Int J Mol Sci. 2009 Apr 23;10(4):1872-95. doi: 10.3390/ijms10041872. Review.

14.

Human apolipoprotein E4 alters the amyloid-beta 40:42 ratio and promotes the formation of cerebral amyloid angiopathy in an amyloid precursor protein transgenic model.

Fryer JD, Simmons K, Parsadanian M, Bales KR, Paul SM, Sullivan PM, Holtzman DM.

J Neurosci. 2005 Mar 16;25(11):2803-10.

15.

Vascular and parenchymal amyloid pathology in an Alzheimer disease knock-in mouse model: interplay with cerebral blood flow.

Li H, Guo Q, Inoue T, Polito VA, Tabuchi K, Hammer RE, Pautler RG, Taffet GE, Zheng H.

Mol Neurodegener. 2014 Aug 9;9:28. doi: 10.1186/1750-1326-9-28.

16.
17.

Cerebrovascular dysfunction in amyloid precursor protein transgenic mice: contribution of soluble and insoluble amyloid-beta peptide, partial restoration via gamma-secretase inhibition.

Han BH, Zhou ML, Abousaleh F, Brendza RP, Dietrich HH, Koenigsknecht-Talboo J, Cirrito JR, Milner E, Holtzman DM, Zipfel GJ.

J Neurosci. 2008 Dec 10;28(50):13542-50. doi: 10.1523/JNEUROSCI.4686-08.2008.

18.

A shift in microglial β-amyloid binding in Alzheimer's disease is associated with cerebral amyloid angiopathy.

Zabel M, Schrag M, Crofton A, Tung S, Beaufond P, Van Ornam J, Dininni A, Vinters HV, Coppola G, Kirsch WM.

Brain Pathol. 2013 Jul;23(4):390-401. doi: 10.1111/bpa.12005. Epub 2012 Nov 28.

19.

Contribution of reactive oxygen species to cerebral amyloid angiopathy, vasomotor dysfunction, and microhemorrhage in aged Tg2576 mice.

Han BH, Zhou ML, Johnson AW, Singh I, Liao F, Vellimana AK, Nelson JW, Milner E, Cirrito JR, Basak J, Yoo M, Dietrich HH, Holtzman DM, Zipfel GJ.

Proc Natl Acad Sci U S A. 2015 Feb 24;112(8):E881-90. doi: 10.1073/pnas.1414930112. Epub 2015 Feb 9.

20.

Pharmacological removal of serum amyloid P component from intracerebral plaques and cerebrovascular Aβ amyloid deposits in vivo.

Al-Shawi R, Tennent GA, Millar DJ, Richard-Londt A, Brandner S, Werring DJ, Simons JP, Pepys MB.

Open Biol. 2016 Feb;6(2):150202. doi: 10.1098/rsob.150202.

Supplemental Content

Support Center